Cagrilintide

Cagrilintide is a long-acting amylin analog that, particularly when combined with semaglutide (CagriSema), offers potent weight loss (up to 20%+ reduction), improved blood glucose management (HbA1c reduction), and enhanced satiety. It works by slowing gastric emptying and acting on the brain to reduce calorie intake, often outperforming other weight-loss treatments.

Key Benefits and Clinical Findings

Significant Weight Reduction: Clinical trials demonstrated that cagrilintide can cause an average weight reduction of 11.5% to 11.8% over 68 weeks. When combined with semaglutide, this effect is intensified, with studies showing up to 20.4% body weight loss, which is comparable to outcomes from bariatric surgery.

Enhanced Satiety and Reduced Appetite: By mimicking the hormone amylin, which is released along with insulin, it promotes a feeling of fullness and reduces overall caloric intake.

Improved Glycemic Control: It helps manage Type 2 diabetes by lowering HbA1c levels and improving insulin sensitivity.

Cardiometabolic Improvements: Beyond weight loss, it has shown positive effects on reducing blood pressure, improving lipid profiles, and reducing C-reactive protein (an inflammatory marker).

Safe and Well-Tolerated: The drug has shown to be safe for use, even at higher doses, making it a promising candidate for long-term obesity management.